- Iopromide
-
-
2026-08-22
- CAS:73334-07-3
- Purity: 0.99
- Iopromide
-
-
2026-08-21
- CAS:73334-07-3
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Iopromide
-
- $403.00
-
2026-08-12
- CAS:73334-07-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 2000KG
|
| | Iopromide Basic information |
| | Iopromide Chemical Properties |
| Melting point | broad (160C transition) | | Boiling point | 840.9±65.0 °C(Predicted) | | density | 2.173±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,2-8°C | | solubility | Freely soluble in water and in dimethyl sulfoxide, practically insoluble in ethanol (96 per cent) and in acetone. | | pka | 10.62±0.70(Predicted) | | form | Solid | | color | White to off-white | | Stability: | Hygroscopic | | Major Application | clinical | | InChI | InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29) | | InChIKey | DGAIEPBNLOQYER-UHFFFAOYSA-N | | SMILES | C1(C(N(CC(O)CO)C)=O)=C(I)C(NC(COC)=O)=C(I)C(C(NCC(O)CO)=O)=C1I | | CAS DataBase Reference | 73334-07-3(CAS DataBase Reference) | | EPA Substance Registry System | 1,3-Benzenedicarboxamide, N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N1-methyl- (73334-07-3) |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | RTECS | CZ2230000 | | HazardClass | 9 | | HS Code | 2924296000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Acute 1
Aquatic Chronic 1 | | Toxicity | LD50 in mice, rats (g iodine/kg body weight): 16.5, 11.4 i.v. (Muetzel) |
| | Iopromide Usage And Synthesis |
| Description | Iopromide is a non-ionic, water-soluble X-ray contrast agent for intravascular administration. Iopromide can cause acute kidney injury and is used in animal models of contrast-induced nephropathy. | | Chemical Properties | White Solid | | Uses | Contrast molecule | | Uses | Labelled Iopromide. Nonionic, injectable radio-contrast medium. Diagnostic aid (radiopaque medium). | | Definition | ChEBI: A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A
ater soluble x-ray contrast agent for intravascular administration. | | Brand name | Ultravist (Berlex). | | General Description | Iopromide is a low-osmolar,nonionic monomer with 48% bound iodine content. It is indicatedfor use in angiography, excretory urography, andnumerous CT procedures. | | Side effects | Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision. | | References | [1] YOUNG-HWAN AHN. The potential utility of iodinated contrast media (ICM) skin testing in patients with ICM hypersensitivity.[J]. Journal of Korean Medical Science, 2015, 30 3: 245-251. DOI: 10.3346/jkms.2015.30.3.245
[2] JIN-YONG PARK. A new micro-computed tomography-based high-resolution blood-brain barrier imaging technique to study ischemic stroke.[J]. Stroke, 2014, 45 8: 2480-2484. DOI: 10.1161/strokeaha.114.006297
[3] KAMAL HASSAN Hassan F. Is hypoalbuminemia a prognostic risk factor for contrast-induced nephropathy in peritoneal dialysis patients[J]. Therapeutics and Clinical Risk Management, 2014, 10: 787-795. DOI: 10.2147/tcrm.s70665
[4] NA WANG. Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism.[J]. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 2015: 2886-2892. DOI: 10.12659/msm.895543 |
| | Iopromide Preparation Products And Raw materials |
|